Reference | Group | N | Age M (SD) | Age Range | Male n (%) | TBSA% M (SD) | Ethnicity n (%) | ||
---|---|---|---|---|---|---|---|---|---|
Reported | Not reported | First Nation | |||||||
Blakeney 2005 [43]. | I | 32 | 14 (1.8) | 12–17 | 9 (28) | 36.8 (25.1) | 32 (100) | 0 (0) | 2 (6)* |
C | 32 | 14.2 (1.9) | 17 (53) | 44.2 (20.6) | 32 (100) | 0 (0) | 0 (0)* | ||
Brown 2014 [44]. | I | 47 | 8.3 (2.5) | 4–13 | 27 (57.5) | 1.9 (2.2) | 47 (100) | 0 (0) | 0 (0) |
C | 52 | 8.2 (2.7) | 33 (63.5) | 1.9 (2.1) | 52 (100) | 0 (0) | 0 (0) | ||
Burns-Nader 2017 [45]. | I | 15 | 7.8 (2.3) | 4–12 | 8 (53) | 9.2 (10.3) | 15 (100) | 0 (0) | 0 (0) |
C | 15 | 7.1 (2.8) | 11 (73) | 6.4 (7.5) | 15 (100) | 0 (0) | 0 (0) | ||
Chester 2018 [46]. | I | 29 | 8.6 (3.4) | 4–15 | 16 (59) | 1.2 (2.0)^ | 0 (0) | 29 (100) | 0 (0)** |
C | 35 | 7.1 (2.7) | 4–15 | 22 (63) | 1.0 (2.0)^ | 0 (0) | 35 (100) | 0 (0)** | |
Elliott 1983 [47] | I | 4 | 8.5 (3.5) | 5–12 | 4 (100) | 21.5 (15.0) | 3 (75) | 1 (25) | 0 (0) |
C | 4 | 6.7 (2.1) | 5–9 | 4 (100) | 32 (24.3) | 1 (25) | 3 (75) | 0 (0) | |
Foertsch 1998 [48] | I | 13 | 5.8 | 3–12 | 12 (52) | 11.4 | 0 (0) | 13 (100) | 0 (0) |
C | 10 | 0 (0) | 10 (100) | 0 (0) | |||||
Hyland 2015 [49] | I | 50 | 2.3 (1.5–4.5)^ | 0–16 | 25 (50) | 0.8 (0.5–2.0)^ | 0 (0) | 50 (100) | 0 (0) |
C | 50 | 2.2 (1.6–3.9)^ | 27 (54) | 0.5 (0.5–2.0)^ | 0 (0) | 50 (100) | 0 (0) | ||
Jeffs 2014 [50]. | IVR | 8 | 14.3 (2.0) | 10–17 | 3 (38) | 7.4 (8.5) | 6 (75) | 2 (25) | 0 (0) |
IPD | 10 | 12.6 (2.1) | 8 (80) | 3.4 (3.3) | 9 (90) | 1 (10) | 0 (0) | ||
C | 10 | 13.9 (2.8) | 8 (80) | 4.7 (6.9) | 10 (100) | 0 (0) | 0 (0) | ||
Kavanagh 1983 [51] | I | 4 | 6.3 (4.4) | 2–11 | 4 (100) | 22.7 (9.1) | 0 (0) | 4 (100) | 0 (0) |
C | 5 | 7.1 (3.8) | 2.5–11.5 | 3 (60) | 37.5 (27.1) | 0 (0) | 5 (100) | 0 (0) | |
Kipping 2012 [52] | I | 20 | 12.6 (1.3) | 11–17 | 13 (65) | 5.1 (6.3) | 0 (0) | 20 (100) | 0 (0) |
C | 21 | 13.5 (1.8) | 15 (71) | 4.7 (4.5) | 0 (0) | 21 (100) | 0 (0) | ||
Miller 2010 [53] | IVGD | 20 | 6.6 (2.5) | 3–10 | 12 (60) | 2.6 (1.4) | 0 (0) | 20 (100) | 0 (0) |
IMMD-D | 20 | 6.6 (2.6) | 13 (65) | 2.8 (1.9) | 0 (0) | 20 (100) | 0 (0) | ||
IMMD-PP | 20 | 5.5 (2.1) | 14 (70) | 4.3 (4.2) | 0 (0) | 20 (100) | 0 (0) | ||
C | 20 | 6.1 (2.1) | 8 (40) | 2.5 (1.4) | 0 (0) | 20 (100) | 0 (0) | ||
Miller 2011 [54] | I | 20 | 6.0 (2.0) | 3–10 | 12 (60) | 2.8 (1.0) | 20 (100) | 0 (0) | 0 (0) |
C | 20 | 5.9 (2.5) | 9 (45) | 2.2 (1.1) | 20 (100) | 0 (0) | 0 (0) | ||
Moore 2015 [55] | IPatient | 12 | 3.0^ | 3–6 | 6 (50) | – | 12 (100) | 0 (0) | 0 (0) |
CPatient | 9 | 3.0^ | 3–5 | 3 (33) | – | 9 (100) | 0 (0) | 0 (0) | |
ICaregiver | 12 | 34^ | 20–44 | 1 (8) | N/A | 0 (0) | 12 (100) | 0 (0) | |
CCaregiver | 9 | 28^ | 23–54 | 1 (11) | N/A | 0 (0) | 9 (100) | 0 (0) | |
Quay 1983 [56] | I | 26 | 5.3 | 0.7–15 | – | 23 (1–81) | 0 (0) | 26 (100) | 0 (0) |
C | 24 | 0 (0) | 24 (100) | 0 (0) | |||||
Sveen 2017 [57] | IPatient | 26 | 5.3 (3.5) | – | 13 (50) | 8.5 (7.0) | 0 (0) | 26 (100 | 0 (0) |
CPatient | 23 | 6.4 (3.8) | 14 (61) | 9.9 (7.0) | 0 (0) | 23 (100) | 0 (0) | ||
ICaregivers | 31 | 36.4 (6.6) | – | 9 (29) | N/A | 0 (0) | 31 (100) | 0 (0) | |
CCaregivers | 31 | 38.3 (5.5) | 11 (35) | N/A | 0 (0) | 31 (100) | 0 (0) | ||
Van der Heijden 2018 [58] | I | 71 | 2.0 (13.1–4.1)^ | 0–13 | 37 (52) | 7 (4–13)^ | 0 (0) | 71 (100) | 0 (0) |
C | 64 | 1.7 (1.3–2.9)^ | 32 (50) | 10 (5–15)^ | 0 (0) | 64 (100) | 0 (0) | ||
Whitehead-Pleaux 2006 [59] | I | 8 | – | 6–16 | 5 (36) | – | 0 (0) | 8 (100) | 0 (0) |
C | 6 | 0 (0) | 6 (100) | 0 (0) |